Circio Holding ASA, a biotechnology company developing circular RNA technology for next generation nucleic acid medicine, has expanded its laboratory operations in Stockholm, Sweden.

The move follows Circio’s recent generation of promising circVec circular RNA expression data in the fields of gene and cell therapy. This expansion will enable Circio to further accelerate pre-clinical development towards its first therapeutic candidates.

Circio’s recently published series of data demonstrates a clear and significant advantage for circVec expression in tissue-specific AAV gene therapy and DNA-format in vivo cell therapy. These results are generating growing interest among a broad life science and industry audience. This has triggered a need for novel laboratories as a platform to support increased research activity and external collaborations.

“This brand-new state-of-the-art laboratory and office space at Novum Labs will substantially expand our footprint and provide an excellent platform for future growth,” said Ola Melin, COO of Circio. “The new link to the Flemingsberg Life Science Cluster and close connection to the Karolinska institute provides access to high quality infrastructure, equipment and competencies. This will be critical as we accelerate our pre-clinical development towards establishing therapeutic circVec candidates to advance towards the clinic.”

The facilities will enable Circio to increase its current R&D productivity, with flexibility for further expansion in the future. Circio will use the increased capacity to progress development of its circVec AAV gene therapy and in vivo cell therapy programs, with the aim to generate in vivo disease model validation during the second half of 2025 and select its first therapeutic candidate during 2026.